ES2651015T3 - Derivados de quinolinona y uso para tratar enfermedades causadas por una mala función de los osteoblastos - Google Patents

Derivados de quinolinona y uso para tratar enfermedades causadas por una mala función de los osteoblastos Download PDF

Info

Publication number
ES2651015T3
ES2651015T3 ES11794858.8T ES11794858T ES2651015T3 ES 2651015 T3 ES2651015 T3 ES 2651015T3 ES 11794858 T ES11794858 T ES 11794858T ES 2651015 T3 ES2651015 T3 ES 2651015T3
Authority
ES
Spain
Prior art keywords
carbon atoms
branched
carbon
linear
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11794858.8T
Other languages
English (en)
Spanish (es)
Inventor
Martial Ruat
Hélène FAURE
Tatiana Gorojankina
André Mann
Maurizio Taddei
Fabrizio Manetti
Antonio Solinas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of ES2651015T3 publication Critical patent/ES2651015T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES11794858.8T 2010-11-16 2011-11-15 Derivados de quinolinona y uso para tratar enfermedades causadas por una mala función de los osteoblastos Active ES2651015T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1004445 2010-11-16
FR1004445A FR2967353B1 (fr) 2010-11-16 2010-11-16 Derives de quinolinone
PCT/IB2011/055096 WO2012066478A1 (fr) 2010-11-16 2011-11-15 Dérivés de quinolinone

Publications (1)

Publication Number Publication Date
ES2651015T3 true ES2651015T3 (es) 2018-01-23

Family

ID=45346524

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11794858.8T Active ES2651015T3 (es) 2010-11-16 2011-11-15 Derivados de quinolinona y uso para tratar enfermedades causadas por una mala función de los osteoblastos

Country Status (7)

Country Link
US (1) US9061997B2 (https=)
EP (1) EP2640388B1 (https=)
JP (1) JP5914509B2 (https=)
CA (1) CA2817388C (https=)
ES (1) ES2651015T3 (https=)
FR (1) FR2967353B1 (https=)
WO (1) WO2012066478A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2967498B1 (fr) * 2010-11-16 2015-01-02 Centre Nat Rech Scient Utilisation de derives de quinolinone comme outil de recherche
JP6647287B2 (ja) 2014-09-23 2020-02-14 アクティブ バイオテック エイビー 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド
JP2020525448A (ja) * 2017-06-23 2020-08-27 ニューヨーク ソサエティ フォー ザ ラプチャード アンド クリップルド メインティニング ザ ホスピタル フォー スペシャル サージェリー ソニックヘッジホッグシグナル伝達経路を介する脊椎円板変性を治療する組成物、使用及び方法
CN114196623B (zh) * 2021-11-12 2024-01-16 青岛大学附属医院 喹啉酮化合物作为骨髓间干细胞成骨分化促进剂的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
HRP20000904A2 (en) * 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
JP2008504233A (ja) * 2004-04-23 2008-02-14 パラテック ファーマシューティカルズ インコーポレイテッド 転写因子調節化合物およびその使用法
CN1955175A (zh) * 2004-10-28 2007-05-02 中国医学科学院药物研究所 香豆素衍生物及其制法和其药物组合物与用途
WO2007124617A1 (fr) * 2006-04-28 2007-11-08 Institute Of Mataria Medica, Chinese Academy Of Medical Sciences Dérivés de coumarine, leurs procédés de préparation, compositions pharmaceutiques et utilisations
WO2008014307A2 (en) * 2006-07-26 2008-01-31 Novartis Ag Inhibitors of undecaprenyl pyrophosphate synthase
US8183236B2 (en) * 2007-04-12 2012-05-22 University Of Southern California Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics

Also Published As

Publication number Publication date
EP2640388B1 (fr) 2017-10-11
WO2012066478A1 (fr) 2012-05-24
FR2967353B1 (fr) 2013-08-16
US20130267559A1 (en) 2013-10-10
JP2013543861A (ja) 2013-12-09
CA2817388C (fr) 2019-12-31
CA2817388A1 (fr) 2012-05-24
FR2967353A1 (fr) 2012-05-18
JP5914509B2 (ja) 2016-05-11
US9061997B2 (en) 2015-06-23
EP2640388A1 (fr) 2013-09-25

Similar Documents

Publication Publication Date Title
ES2528796T3 (es) Benzo[c]fenantridinas pseudobásicas con eficacia, estabilidad y seguridad mejoradas
CN115397810A (zh) 用于治疗cns病症的作为血清素能致幻剂的赛洛辛衍生物
US8816122B2 (en) Prostratin analogs, bryostatin analogs, prodrugs, synthetic methods, and methods of use
KR101421140B1 (ko) 메킬리아 락톤 유도체, 그 약제학적 조성물 및 그 제조방법과 용도
JP7017523B2 (ja) 代謝性疾患および癌の治療のための新規のミトコンドリア脱共役剤
CN106573934B (zh) 瞬时受体电位a1离子通道的抑制
CN107434803A (zh) 组蛋白去甲基化酶抑制剂
CN110950842B (zh) 具有吲哚胺-2,3-双加氧酶抑制活性的喹啉衍生物
CN113801073B (zh) 14-氯-β-榄香烯一氧化氮供体型衍生物及其制备和应用
ES2751627T3 (es) Nuevo derivado de benzodiazepina y uso del mismo
ES2651015T3 (es) Derivados de quinolinona y uso para tratar enfermedades causadas por una mala función de los osteoblastos
CN107635980A (zh) 用于治疗疾病的葡糖神经酰胺合酶抑制剂
CN110023311A (zh) 2-取代的氨基-萘并[1,2-d]咪唑-5-酮类化合物或其药学上可接受的盐
ES3055898T3 (en) Alpha-truxillic acid derivatives and pharmaceutical compositions thereof
CN108276373B (zh) 一种黄酮类化合物及其在抗癌症药物中的应用
ES2963054T3 (es) Derivado de guanidina
CN101974016A (zh) 酰胺类化合物及其制备方法和用途
JP2004510770A (ja) ７−カルボキシフラボン誘導体、調製法および治療適用
US20220016108A1 (en) Quinolines that modulate serca and their use for treating disease
CN108409737B (zh) 4-甲氧基苯基取代四氢-β-咔啉哌嗪二酮类衍生物及其应用
CA3164617A1 (en) Selective cdk4/6 inhibitor cancer therapeutics
CN107629041B (zh) 查尔酮类衍生物、其制备方法及其在医药上的应用
AU2007280400A1 (en) Phenyl-prenyl-ether derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
CN109942665A (zh) 雷公藤内酯醇衍生物及其制备方法和应用
KR102421065B1 (ko) 새로운 퀴논-인돌리진 하이브리드 유도체 제조방법 및 이를 포함하는 항암제 조성물